Morgan Stanley Call 550 LONN 20.0.../ DE000MG83X50 /
| 08/11/2024 14:32:29 | Var.+0.050 | Denaro22:00:39 | Lettera22:00:39 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
|---|---|---|---|---|---|---|---|
| 0.510EUR | +10.87% | - Quantità in denaro: - |
- Quantità in lettera: - |
LONZA N | 550.00 CHF | 20/06/2025 | Call |
GlobeNewswire
26/08
Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences
GlobeNewswire
23/08
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire
08/08
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
06/08
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
14/06
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire
30/05
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire
15/05
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire
08/05
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
04/04
Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire
04/04
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...
GlobeNewswire
27/02
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
04/01
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire
19/12/2023
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...
GlobeNewswire
09/12/2023
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...
GlobeNewswire
07/12/2023
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...
GlobeNewswire
06/11/2023
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
16/10/2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...
GlobeNewswire
02/10/2023
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire
20/09/2023
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
